Notification regarding unquoted securities - CUV
Melbourne, Australia, 16 September 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...
Read More
Presentation H.C. Wainwright Global Investment Conference
Melbourne, Australia, 14 September 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...
Read More
CLINUVEL Kommuniqué IV
Sehr geehrte Aktionärinnen und Aktionäre, liebe Freunde, Einleitung Zufrieden blicken wir auf...
Read More
CLINUVEL Investor Webinar Financial Results Year Ended 30 June 2021
Melbourne, Australia, 27 August 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...
Read More
CLINUVEL Communiqué IV
Dear Shareholders, Friends Introduction With satisfaction, we look back at an eventful...
Read More
Corporate Presentation - FY2021 Results
Melbourne, Australia, 26 August 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...
Read More
Appendix 4E and Preliminary Financial Report
Melbourne, Australia, 26 August 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...
Read More
CLINUVEL Delivers Record Revenues and Profit
Melbourne, Australia, 26 August 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...
Read More
Dividend/Distribution - CUV
Melbourne, Australia, 26 August 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...
Read More
SCIENTIFIC COMMUNIQUÉ XI: Developing Novel Treatments for Arterial Ischaemic Stroke Patients
Abstract One in four people globally will suffer from a stroke in...
Read More
Afamelanotide well tolerated by first stroke patients
CLINUVEL’s drug afamelanotide was well tolerated by the first three arterial ischaemic...
Read More
Appendix 4C & Activity Report
Melbourne, Australia, 29 July 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...
Read More
Insider Insights III: Willem Blijdorp - Challenges & the Future
CLINUVEL today launches the third and final part of the Insider Insights...
Read More
Insider Insights II: Willem Blijdorp - CLINUVEL’s Products, People & Social Purpose
CLINUVEL today launches the next part of the Insider Insights series, featuring...
Read More
Appendix 3Y Change of Director's Interest Notice
Information or documents not available now must be given to ASX as...
Read More